pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$MISTMilestone Pharmaceuticals Inc.

$MIST
Montreal, Quebec, CAupdated 3mo ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
1
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Marketed: 1
1Marketed
Marketed
etripamil
Atrial Fibrillation

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302terminatedn=169
  • phase2ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2completedn=69
  • phase3Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).terminatedn=1,097
  • phase3Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303completedn=1,116
🐶 Hiring Signal
No open roles indexed yet — view Milestone Pharmaceuticals Inc. jobs →

News

  • Milestone cuts 20% of staff as Cardamyst sales hit $1M in Q3
    Milestone Pharmaceuticals is cutting costs and staff following the FDA approval of its heart arrhythmia treatment, with two top executives departing the leadership team. The company said in its thi…
    endpoints · 5d ago
identifiers
ticker
$MIST
SEC CIK
0001408443
country
CA
source
sec_tickers
top tags
Atrial Fibrillation1Cardiology1
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 26m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?